SEP 11, 2019 9:06 AM PDT

Diagnosis and Treatment of Neurosarcoidosis

WRITTEN BY: Dena Aruta

Sarcoidosis is a multisystem inflammatory disease characterized by the formation of non-caseating granulomas in the affected organs. The majority of people diagnosed with sarcoidosis have it in their lungs (90%), but it can affect any organ system in the body. The etiology is currently unknown, however, it is thought to have both an environmental and genetic component. Sarcoidosis affects all races, ages, and genders although African-American women have the highest rates and poorer prognoses. The course that it takes is highly variable, but those who have chronic disease often have more disabling symptoms and reduction in quality of life. 

 

Mareye et al. provide an overview of neurosarcoidosis. It is not as prevalent as the pulmonary form and affects approximately 5-10% of people diagnosed. Any part of the nervous system can be affected including the brain, spinal cord, meninges, peripheral nerves, and cranial nerves. The most common presentation is cranial neuropathy with the facial nerves most frequently involved. Approximately 50-70% of people diagnosed with neurosarcoidosis have cranial neuropathy. 

Diagnosis can be problematic because there are no definitive tests that identify it, and there is a lack of agreement among specialists concerning specific criteria required for diagnosis. The Neurosarcoidosis Consortium Consensus Committee consisting of 10 neurologists and four pulmonologists developed new criteria to diagnose neurosarcoidosis, and they issued a statement published in JAMA Neurology. The key elements include: (1) other granulomatous diseases have to be ruled out due to  overlapping symptoms, (2) diagnosis based on most possible, probable, or definite since tissue biopsy of neural tissue is rarely an option, (3) assess for systemic involvement as well as neurosarcoidosis, and (4) high-resolution CT scan or PET scan recommended if chest x-ray is normal.

In possible neurosarcoidosis, there is no histologic confirmation of non-caseating granulomas; probable has histologic identification in extra-neurologic tissues and definite has it in neurological tissue. 

Authors of the consensus committee stated that the “development of criteria for diagnosis is essential for the design of clinical trials for neurosarcoidosis.” In addition, Barney Stern, MD, FAAN, professor of neurology at Johns Hopkins University and a lead author of the paper said:  “Our goal is to promote optimal patient care,” and “Part of the challenge is that you want to treat rapidly, but you have to balance the speed and intensity of treatment with the goal of having a definitive diagnosis.”

Small fiber neuropathy (SFN) is another manifestation of neurosarcoidosis, which can be invasive. Its diagnosis can be difficult and is usually made through a skin biopsy. Other diagnostic options for SFN include an SFN screening list and corneal confocal microscopy (this hasn't been validated and isn't widely available). Unfortunately, there are no approved treatments for SFN; however, some success has been seen with tumor necrosis factor-α inhibitors.

There have been no clinical trials for treatment therapies, but it is recommended that treatment intensity is based on disease severity. Medications that have been used include the gold standard for sarcoidosis, prednisone, as well as methotrexate, azathioprine, mycophenolate mofetil, or tumor necrosis factor-α inhibitors (infliximab or adalimumab). 

Because of the burden of disease and treatment costs, further research and more clinical trials need to be performed to develop more effective treatments for neurosarcoidosis.

About the Author
  • After earning my Bachelor of Science degree in biology/chemistry from Virginia Polytechnic Institute and State University (aka Va. Tech), I went on to complete clinical rotations in laboratory medicine at Roanoke Memorial Hospital. I spent the next 21 years working in healthcare as a clinical microbiologist. In 2015, I combined my fascination with medicine and passion for writing into a freelance career, and I haven't looked back. Even though my expertise is in microbiology and infectious diseases, I'm adept at writing about any medical topic. Being a freelance writer allows me to pursue a career where I can work at home with my two feline assistants, Luke and Grace. I'm a firm supporter of animal rights and volunteer for a local rescue during my free time. 
You May Also Like
MAR 18, 2021
Health & Medicine
Cannabis Not as Promising as Hoped for PTSD
MAR 18, 2021
Cannabis Not as Promising as Hoped for PTSD
Medical marijuana is used fairly routinely as a treatment for veterans suffering with PTSD (post traumatic stress syndro ...
APR 01, 2021
Microbiology
Mapping the Wild Microbiome to Search for Therapeutic Agents
APR 01, 2021
Mapping the Wild Microbiome to Search for Therapeutic Agents
Many people think of bacteria as disgusting germs, but there are plenty of important bacterial species that provide us w ...
APR 09, 2021
Microbiology
A Neurological Disorder Sometimes Seen After Vaccinations
APR 09, 2021
A Neurological Disorder Sometimes Seen After Vaccinations
Functional neurological disorder (FND) is a real neuropsychiatric disorder that some people have after medical procedure ...
APR 10, 2021
Drug Discovery & Development
How New ADHD Drug for Children Differs from Adderall
APR 10, 2021
How New ADHD Drug for Children Differs from Adderall
Over 1 in 10 children in the US aged between 5 and 17 have been diagnosed with attention deficit hyperactivity ...
APR 13, 2021
Microbiology
Learning How TORCH Pathogens Cause Brain Malformations
APR 13, 2021
Learning How TORCH Pathogens Cause Brain Malformations
The term TORCH pathogens refers to a group of viruses including Toxoplasma gondii, Rubella, Herpes Simplex Viruses 1 and ...
APR 15, 2021
Health & Medicine
Concerns Over Delta-8?
APR 15, 2021
Concerns Over Delta-8?
Delta-8-THC is a hemp byproduct that’s being exploited by an apparent loophole in federal law that allows its unfe ...
Loading Comments...